Psoriasis drug may lower heart disease risk

Psoriasis drug may lower heart disease risk

Psoriasis, a chronic inflammatory condition, is one of the most common skin disorders in the United States. It affects more than 100 million people worldwide. The skin cells of people with psoriasis multiply faster than normal, which produces raised red bumps on the skin, often on the knees, scalp, and elbows. Though psoriasis affects such a large proportion of adults, its causes are unclear, and it cannot currently be cured. Over the years, a link has been found between psoriasis and an increased risk of cardiovascular disease. This relationship is particularly pronounced in individuals who have severe psoriasis.
Ustekinumab, sold as Stelara, is an antibody that interferes with the body's inflammatory response. It is prescribed for people whose psoriasis has not responded well to other treatments, or who cannot tolerate other available medicines. The drug has also been approved by the Food and Drug Administration (FDA) to treat Crohn's disease.
Courtesy: medicalnewstoday.com/